Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
E-2511 by Eisai for Alzheimer's Disease: Likelihood of Approval
E-2511 is under clinical development by Eisai and currently in Phase I for Alzheimer's Disease. According to GlobalData, Phase I...
Lenvatinib mesylate by Eisai for Lung Adenocarcinoma: Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase...
Lenvatinib mesylate by Eisai for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Lenvatinib mesylate by Eisai for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
Lenvatinib mesylate by Eisai for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer)....
Lenvatinib mesylate by Eisai for Neuroendocrine Carcinoma: Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData, Phase...
E-2086 by Eisai for Narcolepsy: Likelihood of Approval
E-2086 is under clinical development by Eisai and currently in Phase I for Narcolepsy. According to GlobalData, Phase I drugs...
Lenvatinib mesylate by Eisai for High-Grade Glioma: Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for High-Grade Glioma. According to GlobalData, Phase...
Lenvatinib mesylate by Eisai for Rhabdomyosarcoma: Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase II...
Lenvatinib mesylate by Eisai for Non-Small Cell Lung Cancer: Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Lenvatinib mesylate by Eisai for Ewing Sarcoma: Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Ewing Sarcoma. According to GlobalData, Phase...
Lenvatinib mesylate by Eisai for Metastatic Melanoma: Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...
Lenvatinib mesylate by Eisai for Colorectal Cancer: Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
Lenvatinib mesylate by Eisai for Osteosarcoma: Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II...
Lenvatinib mesylate by Eisai for Metastatic Biliary Tract Cancer: Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Metastatic Biliary Tract Cancer. According to...
Lenvatinib mesylate by Eisai for Salivary Gland Cancer: Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Salivary Gland Cancer. According to GlobalData,...
Lenvatinib mesylate by Eisai for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...
Lenvatinib mesylate by Eisai for Ovarian Cancer: Likelihood of Approval
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Eribulin mesylate by Eisai for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Eribulin mesylate is under clinical development by Eisai and currently in Phase III for Metastatic Transitional (Urothelial) Tract Cancer. According...
E-7820 by Eisai for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
E-7820 is under clinical development by Eisai and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData,...